// App-Quantinova.ai

: Using controlled and real-world data in concert to assess survival benefits in pulmonary arterial hypertension: Insights from SERAPHIN and REVEAL

Researchers

Presenter

  • Raymond Benza

Principal Investigators

  • Hajime Uno

  • Richard Channick

  • Marion Delcroix

  • Harrison Farber

  • Nazzareno Gali

  • Hossein A. Ghofrani

  • Brian Hennessy

  • Pavel Jansa

  • Michael McGoon

  • Sanjay Mehta

  • Loc Perchenet

  • Toms Pulido

  • Daniel M. Rosenberg

  • Lewis J. Rubin

  • Bhagavatula K. S. Sastry

  • Grald Simonneau

  • Olivier Sitbon

  • Rogerio Souza

  • Lee-Jen J. Wei

Medical Centers

  • Allegheny General Hospital, Pittsburgh, United States of America

  • F.Chopin Hospital, Otwock, Poland

  • Dana-Farber Cancer Institute, Boston, MA, United States

  • Pediatrics, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States

  • University Hospitals Leuven and KU Leuven, Leuven, Belgium

  • Boston University School of Medicine, Boston, MA, United States

  • Univeristy of Bologna, Bologna, Italy

  • University of Giessen and Marburg Lung Center (UGMLC) - Giessen (Germany), and Department of Medicine, Imperial College London, London, United Kingdom

  • Actelion Pharmaceuticals Ltd, Allschwil, Switzerland

  • Charles Univ and VFN, Prague, Czech Republic

  • Mayo Clinic - Rochester - United States of America

  • London Health Sciences Centre - University Hospital, London, ON, Canada

  • Ignacio Chávez National Heart Institute, Mexico City, Mexico

  • San Diego Medical School, University of California, San Diego, United States of America

  • Omega Hospitals, Hyderabad, India

  • Hôpital de Bicêtre, Le Kremlin-Bicêtre, Paris, France

  • INCOR Heart Institute, University of São Paulo, São Paulo, Brazil

  • Tufts University, Boston, United States of America

Locations

  • United States

  • Poland

  • Belgium

  • Italy

  • United Kingdom

  • Switzerland

  • Czech Republic

  • Canada

  • Mexico

  • India

  • France

  • Brazil

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Pulmonary arterial hypertension

Biomarkers

  • AKT Serine

Drug/Treatment

  • macitentan

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Observational

  • Controlled

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved